US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

CITIUS ONCOLOGY INC

1.05

+0.08018.26%

Post-market: 1.050.00000.00%19:10 EDT

Volume:126.52K

Turnover:130.30K

Market Cap:75.14M

PE:-2.83

High:1.09

Open:0.9730

Low:0.9693

Close:0.9700

Loading ...

Overview Company News Filings

Citius Oncology Cut to Hold From Buy by Maxim Group

Maxim Downgrades Citius Oncology to Hold From Buy

MT Newswires Live

Citius Oncology downgraded to Hold from Buy at Maxim

Citius Oncology Inc : Maxim Group Cuts to Hold From Buy

THOMSON REUTERS

BRIEF-Citius Oncology, Inc. Reports Fiscal Second Quarter 2025 Financial Results And Provides Business Update

Citius Oncology Q2 EPS $(0.11) Misses $(0.09) Estimate

Citius Pharmaceuticals Reports Q2 2025 Financials: Net Loss Widens to $11.5 Million, EPS at ($1.27)

Citius Oncology Inc: Qtrly Net Loss per Share $-0.11

THOMSON REUTERS

Citius Oncology, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update

THOMSON REUTERS

Press Release: Citius Oncology, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update

BRIEF-Citius Oncology Inc - Receives Nasdaq Notice For Bid Price Non-Compliance - SEC Filing

Citius Oncology Inc - Receives Nasdaq Notice for Bid Price Non-Compliance - SEC Filing

THOMSON REUTERS

Wall Street Set to Open Lower Monday as Investors Gird for More Tariffs, Await Key Manufacturing Data

MT Newswires Live

Investors Brace for 'Liberation Day' as US Futures Trend Sharply Lower in Monday's Premarket

MT Newswires Live

Citius Oncology Q1 2025 GAAP EPS $(1.30) Misses $(0.06) Estimate

Press Release: Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update

Citius Pharmaceuticals and Citius Oncology announce J-Code issued for Lymphir

Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for Lymphir by Centers for Medicare and Medicaid Services

THOMSON REUTERS

Citius Pharmaceuticals Inc: Permanent J-Code (J9161) Expected to Be Effective April 1, 2025

THOMSON REUTERS

Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/CTOR/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CTOR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CTOR\",,,,,undefined,":{"symbol":"CTOR","market":"US","secType":"STK","nameCN":"CITIUS ONCOLOGY INC","latestPrice":1.0501,"timestamp":1749240000000,"preClose":0.97,"halted":0,"volume":126518,"hourTrading":{"tag":"盘后","latestPrice":1.0501,"preClose":1.0501,"latestTime":"19:10 EDT","volume":1269,"amount":1335.35,"timestamp":1749251414083},"delay":0,"floatShares":5502787,"shares":71552402,"eps":-0.371137,"marketStatus":"Market Closed","change":0.0801,"latestTime":"06-06 16:00:00 EDT","open":0.973,"high":1.09,"low":0.9693,"amount":130299.16755520001,"amplitude":0.124433,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.371137,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1749456000000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":0.97,"preHourTrading":{"tag":"盘前","latestPrice":0.97,"preClose":0.97,"latestTime":"08:29 EDT","volume":1753,"amount":1701.37863768,"timestamp":1749212985414},"postHourTrading":{"tag":"盘后","latestPrice":1.0501,"preClose":1.0501,"latestTime":"19:10 EDT","volume":1269,"amount":1335.35,"timestamp":1749251414083},"volumeRatio":4.336521011838304},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CTOR\",,,,,undefined,":{"symbol":"CTOR","floatShares":5502787,"roa":"-22.41%","roe":"-93.64%","lyrEps":-0.310765,"volumeRatio":4.336521011838304,"shares":71552402,"dividePrice":0,"high":1.09,"amplitude":0.124433,"preClose":0.97,"low":0.9693,"week52Low":0.5506,"pbRate":"2.11","week52High":49,"institutionHeld":0,"latestPrice":1.0501,"eps":-0.371137,"divideRate":0,"volume":126518,"delay":0,"ttmEps":-0.371137,"open":0.973,"prevYearClose":1.15,"prevWeekClose":0.9,"prevMonthClose":0.9,"prevQuarterClose":0.93,"fiveDayClose":0.9,"twentyDayClose":0.845,"sixtyDayClose":0.789},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CTOR\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2537158586","title":"Citius Oncology Cut to Hold From Buy by Maxim Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2537158586","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537158586?lang=en_us&edition=fundamental","pubTime":"2025-05-23 23:12","pubTimestamp":1748013120,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CTOR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 23, 2025 11:12 ET (15:12 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTOR","BK4139"],"gpt_icon":0},{"id":"2537367791","title":"Maxim Downgrades Citius Oncology to Hold From Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2537367791","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537367791?lang=en_us&edition=fundamental","pubTime":"2025-05-23 20:17","pubTimestamp":1748002641,"startTime":"0","endTime":"0","summary":"Maxim Downgrades Citius Oncology to Hold From Buy","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CTOR"],"gpt_icon":0},{"id":"2537813614","title":"Citius Oncology  downgraded to Hold from Buy at Maxim","url":"https://stock-news.laohu8.com/highlight/detail?id=2537813614","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537813614?lang=en_us&edition=fundamental","pubTime":"2025-05-23 19:55","pubTimestamp":1748001308,"startTime":"0","endTime":"0","summary":"Maxim downgraded Citius Oncology (CTOR) to Hold from Buy. Published first on TheFly – the ultimate source for real-time, market-moving breaking fin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/citius-oncology-downgraded-to-hold-from-buy-at-maxim-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/citius-oncology-downgraded-to-hold-from-buy-at-maxim-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CTOR"],"gpt_icon":0},{"id":"2537351201","title":"Citius Oncology Inc : Maxim Group Cuts to Hold From Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2537351201","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537351201?lang=en_us&edition=fundamental","pubTime":"2025-05-23 19:45","pubTimestamp":1748000741,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250523:nFWN3RV1ZS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CTOR"],"gpt_icon":0},{"id":"2535888956","title":"BRIEF-Citius Oncology, Inc. Reports Fiscal Second Quarter 2025 Financial Results And Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2535888956","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535888956?lang=en_us&edition=fundamental","pubTime":"2025-05-15 04:52","pubTimestamp":1747255977,"startTime":"0","endTime":"0","summary":"BRIEF-Citius Oncology, Inc. Reports Fiscal Second Quarter 2025 Financial Results And Provides Business UpdateMay 14 (Reuters) - Citius Oncology Inc CTOR.O:CITIUS ONCOLOGY, INC. REPORTS FISCAL SECOND Q","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nTUA8WBQWB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CTOR"],"gpt_icon":0},{"id":"2535888510","title":"Citius Oncology Q2 EPS $(0.11) Misses $(0.09) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2535888510","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535888510?lang=en_us&edition=fundamental","pubTime":"2025-05-15 04:49","pubTimestamp":1747255750,"startTime":"0","endTime":"0","summary":"Citius Oncology Q2 EPS $(0.11) Misses $(0.09) Estimate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45422224/citius-oncology-q2-eps-0-11-misses-0-09-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTOR"],"gpt_icon":0},{"id":"2535300062","title":"Citius Pharmaceuticals Reports Q2 2025 Financials: Net Loss Widens to $11.5 Million, EPS at ($1.27)","url":"https://stock-news.laohu8.com/highlight/detail?id=2535300062","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535300062?lang=en_us&edition=fundamental","pubTime":"2025-05-15 04:33","pubTimestamp":1747254804,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Citius Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 14, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nNDL98ZMDB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JEF","CTXR","CTOR"],"gpt_icon":0},{"id":"2535000792","title":"Citius Oncology Inc: Qtrly Net Loss per Share $-0.11","url":"https://stock-news.laohu8.com/highlight/detail?id=2535000792","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535000792?lang=en_us&edition=fundamental","pubTime":"2025-05-15 04:30","pubTimestamp":1747254605,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nTUA8WBQWB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CTOR"],"gpt_icon":0},{"id":"2535000549","title":"Citius Oncology, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2535000549","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535000549?lang=en_us&edition=fundamental","pubTime":"2025-05-15 04:30","pubTimestamp":1747254605,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nTUA8WBQWB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CTOR"],"gpt_icon":0},{"id":"2535000668","title":"Press Release: Citius Oncology, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2535000668","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535000668?lang=en_us&edition=fundamental","pubTime":"2025-05-15 04:30","pubTimestamp":1747254600,"startTime":"0","endTime":"0","summary":"CRANFORD, N.J., May 14, 2025 /PRNewswire/ -- Citius Oncology, Inc.  , a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported business and financial results for the fiscal second quarter ended March 31, 2025.\"In Q2 2025, Citius Oncology advanced its transformation from a development-stage company to a commercial-stage organization. Following FDA approval of LYMPHIR, we intensified our focus on disciplined capital deployment and operational execution to support the success of our planned U.S. launch,\" said Leonard Mazur, Chairman and CEO of Citius Oncology and Citius Pharmaceuticals.G&A expenses were $2.2 million for the quarter ended March 31, 2025, as compared to $1.4 million for the quarter ended March 31, 2024. For the six months ended March 31, 2025, G&A expenses were $5.5 million, as compared to $2.9 mill","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CTOR"],"gpt_icon":0},{"id":"2530160574","title":"BRIEF-Citius Oncology Inc - Receives Nasdaq Notice For Bid Price Non-Compliance - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2530160574","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530160574?lang=en_us&edition=fundamental","pubTime":"2025-04-26 04:25","pubTimestamp":1745612734,"startTime":"0","endTime":"0","summary":"BRIEF-Citius Oncology Inc - Receives Nasdaq Notice For Bid Price Non-Compliance - SEC FilingApril 25  - Citius Oncology Inc CTOR.O:CITIUS ONCOLOGY INC - RECEIVES NASDAQ NOTICE FOR BID PRICE NON-COMPLIANCE - SEC FILINGSource text: [ID:n0001213900-25-035575]Further company coverage: CTOR.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250425:nFWN3R326S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CTOR"],"gpt_icon":0},{"id":"2530605201","title":"Citius Oncology Inc - Receives Nasdaq Notice for Bid Price Non-Compliance - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2530605201","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530605201?lang=en_us&edition=fundamental","pubTime":"2025-04-26 04:24","pubTimestamp":1745612661,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250425:nFWN3R326S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CTOR","BK4139"],"gpt_icon":0},{"id":"2523787941","title":"Wall Street Set to Open Lower Monday as Investors Gird for More Tariffs, Await Key Manufacturing Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2523787941","media":"MT Newswires Live","labels":["economic"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523787941?lang=en_us&edition=fundamental","pubTime":"2025-03-31 21:02","pubTimestamp":1743426126,"startTime":"0","endTime":"0","summary":"US stocks look set to open lower in Monday's trading session as investors brace for President Donald Trump's \"Liberation Day\" tariff announcements on Wednesday. Key manufacturing data is also set for ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"economic","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MWYN","RKT","BK4190","DMN","BK4220","AUID","BK4091","BK4122","BK4547","BK4104","PCVX","BK4097","ISBC","GATE","BK4195","IE0009354923.USD","LU0053671581.USD","BK4539","RKT.AU","BK7084","HMST","BK4211","NWTG","COOP","BK4229","BK4099","BK4139","DIBS","CTOR"],"gpt_icon":0},{"id":"2523946582","title":"Investors Brace for 'Liberation Day' as US Futures Trend Sharply Lower in Monday's Premarket","url":"https://stock-news.laohu8.com/highlight/detail?id=2523946582","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523946582?lang=en_us&edition=fundamental","pubTime":"2025-03-31 20:16","pubTimestamp":1743423386,"startTime":"0","endTime":"0","summary":"US stock futures are sharply lower in Monday's premarket activity as investors brace for President Donald Trump's \"Liberation Day\" tariffs announcement Wednesday, and await key manufacturing data comi","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4220","LU0053671581.USD","PCVX","BK4190","MWYN","BK4104","GATE","IE0009354923.USD","CTOR","BK4122","NWTG","BK4539","ISBC","BK4139","DIBS","BK4211"],"gpt_icon":0},{"id":"2511561096","title":"Citius Oncology Q1 2025 GAAP EPS $(1.30) Misses $(0.06) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2511561096","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511561096?lang=en_us&edition=fundamental","pubTime":"2025-02-15 05:33","pubTimestamp":1739568832,"startTime":"0","endTime":"0","summary":"Citius Oncology (NASDAQ:CTOR) reported quarterly losses of $(1.30) per share which missed the analyst consensus estimate of $(0.06) by 2066.67 percent.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/02/43749115/citius-oncology-q1-2025-gaap-eps-1-30-misses-0-06-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Citius Oncology Q1 2025 GAAP EPS $(1.30) Misses $(0.06) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTOR"],"gpt_icon":0},{"id":"2511261061","title":"Press Release: Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2511261061","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511261061?lang=en_us&edition=fundamental","pubTime":"2025-02-15 05:30","pubTimestamp":1739568600,"startTime":"0","endTime":"0","summary":"CRANFORD, N.J., Feb. 14, 2025 /PRNewswire/ -- Citius Oncology, Inc.  , a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported business and financial results for the fiscal first quarter ended December 31, 2024.Fiscal First Quarter 2025 Business Highlights and Subsequent Developments. -- Engaged Jefferies as exclusive financial advisor to assist in evaluating. strategic alternatives aimed at maximizing shareholder value, with. -- Progressed commercial readiness for the planned launch of LYMPHIR in. the first half of 2025, with key initiatives including:. -- Manufactured sufficient inventory for launch and initial sales. diftitox-cxdl, for intravenous use, 1 microgram) for LYMPHIR,assigned by the Centers for Medicare & Medicaid Services ,with an expected effective date of April 1, 2025;potential as an immuno-oncology combination therapy being conducted at. -- R&D expenses were $1.3 million for the first ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2637428348.USD","CTOR","03160","BK4585","BK4139","BK4604","CMS","BK4080","LU1894683264.USD","BK4208","LU1894683348.USD","LU2346227817.USD","BK4588","BK4555","BK4099","BK4231","TM","SITC"],"gpt_icon":0},{"id":"2509713472","title":"Citius Pharmaceuticals and Citius Oncology announce J-Code issued for Lymphir","url":"https://stock-news.laohu8.com/highlight/detail?id=2509713472","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509713472?lang=en_us&edition=fundamental","pubTime":"2025-02-06 22:01","pubTimestamp":1738850467,"startTime":"0","endTime":"0","summary":"Citius Pharmaceuticals (CTXR) and its oncology-focused subsidiary, Citius Oncology (CTOR) announced that Lymphir has been assigned a unique, perman...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/citius-pharmaceuticals-and-citius-oncology-announce-j-code-issued-for-lymphir?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/citius-pharmaceuticals-and-citius-oncology-announce-j-code-issued-for-lymphir?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CTXR","BK4139","BK4007","CTOR"],"gpt_icon":0},{"id":"2509637279","title":"Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for Lymphir by Centers for Medicare and Medicaid Services","url":"https://stock-news.laohu8.com/highlight/detail?id=2509637279","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509637279?lang=en_us&edition=fundamental","pubTime":"2025-02-06 21:55","pubTimestamp":1738850132,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250206:nFWN3OX1PD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CTXR","CTOR","BK4007","BK4139"],"gpt_icon":0},{"id":"2509027963","title":"Citius Pharmaceuticals Inc: Permanent J-Code (J9161) Expected to Be Effective April 1, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2509027963","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509027963?lang=en_us&edition=fundamental","pubTime":"2025-02-06 21:55","pubTimestamp":1738850132,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250206:nFWN3OX1PD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CTXR","CTOR","BK4139"],"gpt_icon":0},{"id":"2509027926","title":"Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services","url":"https://stock-news.laohu8.com/highlight/detail?id=2509027926","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509027926?lang=en_us&edition=fundamental","pubTime":"2025-02-06 21:55","pubTimestamp":1738850100,"startTime":"0","endTime":"0","summary":"Permanent J-Code  expected to be effective April 1, 2025. LYMPHIR is approved by the U.S. Food and Drug Administration  for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma  after at least one prior systemic therapy.CRANFORD, N.J., Feb. 6, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc.   and its oncology-focused subsidiary, Citius Oncology, Inc.  , today announced that LYMPHIR  has been assigned a unique, permanent Healthcare Common Procedure Coding System  J-code  by the Centers for Medicare & Medicaid Services .Effective April 1, 2025, healthcare providers may use the permanent J-code, J9161 , when submitting claims for LYMPHIR.\"The establishment of a permanent J-code marks a critical milestone in supporting patient access to LYMPHIR, providing coding clarity for physicians and facilities who administer LYMPHIR, and facilitating reimbursement. This achievement is a key step in ensuring that LYMPHIR is accessible to patients with com","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/citius-pharmaceuticals-citius-oncology-announce-135500837.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/citius-pharmaceuticals-citius-oncology-announce-135500837.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4113","BK4208","BK4539","CTXR","BK4526","LU1894683264.USD","LU1894683348.USD","CTOR","LU2637428348.USD","BK4585","BK4563","BK4145","LU2346227817.USD","BK4139","LU2045819591.USD","MF","CMS","LU2125910500.SGD","BK4588"],"gpt_icon":1}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":34,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CTOR\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CTOR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CTOR\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":1,"updateTime":1748059200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CTOR\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CTOR","date":"2025-06-06","current":-2.671453,"percent":0.748744,"low":-8.240776,"twenty":-4.755189,"median":-3.805483,"eighty":-2.487546,"high":-1.770477,"avg":-3.888279,"sd":1.434871,"marketCap":69405829},"quantilePoints":[{"date":"2024-08-23","current":-7.506449,"twenty":-8.175502,"median":-7.996,"eighty":-7.800179,"marketCap":131199450},{"date":"2024-08-30","current":-6.464428,"twenty":-8.028637,"median":-7.567643,"eighty":-6.639734,"marketCap":126208166},{"date":"2024-09-06","current":-6.847911,"twenty":-7.922567,"median":-7.149219,"eighty":-6.405992,"marketCap":133695091},{"date":"2024-09-13","current":-5.989639,"twenty":-7.726747,"median":-6.50095,"eighty":-6.274513,"marketCap":116938640},{"date":"2024-09-20","current":-6.099206,"twenty":-7.555404,"median":-6.464428,"eighty":-5.97503,"marketCap":119077761},{"date":"2024-09-27","current":-5.222673,"twenty":-7.472896,"median":-6.354861,"eighty":-5.953117,"marketCap":101964790},{"date":"2024-10-04","current":-4.309619,"twenty":-7.088957,"median":-6.190511,"eighty":-5.617113,"marketCap":84138777},{"date":"2024-10-11","current":-3.542653,"twenty":-6.749301,"median":-6.099206,"eighty":-5.018149,"marketCap":69164927},{"date":"2024-10-18","current":-3.944397,"twenty":-6.661648,"median":-5.953117,"eighty":-4.16353,"marketCap":77008372},{"date":"2024-10-25","current":-4.399098,"twenty":-6.559386,"median":-5.916595,"eighty":-4.331532,"marketCap":85885727},{"date":"2024-10-31","current":-4.419185,"twenty":-6.486341,"median":-5.66094,"eighty":-4.324228,"marketCap":86277899},{"date":"2024-11-08","current":-4.602892,"twenty":-6.464428,"median":-5.16789,"eighty":-4.287705,"marketCap":89864492},{"date":"2024-11-15","current":-3.904222,"twenty":-6.464428,"median":-4.930496,"eighty":-4.287705,"marketCap":76224028},{"date":"2024-11-22","current":-3.564201,"twenty":-6.420601,"median":-4.784407,"eighty":-3.944397,"marketCap":69585621},{"date":"2024-11-29","current":-3.356755,"twenty":-6.347557,"median":-4.693102,"eighty":-3.842134,"marketCap":65535551},{"date":"2024-12-06","current":-5.916595,"twenty":-6.296426,"median":-4.747885,"eighty":-3.776395,"marketCap":115512559},{"date":"2024-12-13","current":-3.907874,"twenty":-6.201468,"median":-4.620605,"eighty":-3.842134,"marketCap":76295332},{"date":"2024-12-20","current":-3.871352,"twenty":-6.164946,"median":-4.528752,"eighty":-3.842134,"marketCap":75582291},{"date":"2024-12-27","current":-3.50613,"twenty":-6.135728,"median":-4.435255,"eighty":-3.725263,"marketCap":68451887},{"date":"2025-01-03","current":-4.012144,"twenty":-6.10651,"median":-4.399098,"eighty":-3.717959,"marketCap":84851818},{"date":"2025-01-10","current":-3.992285,"twenty":-6.033466,"median":-4.399098,"eighty":-3.747177,"marketCap":84431834},{"date":"2025-01-17","current":-4.465946,"twenty":-5.967726,"median":-4.376046,"eighty":-3.723807,"marketCap":94449170},{"date":"2025-01-24","current":-4.296782,"twenty":-5.953117,"median":-4.35308,"eighty":-3.739872,"marketCap":90871550},{"date":"2025-01-31","current":-4.262949,"twenty":-5.953117,"median":-4.346141,"eighty":-3.761786,"marketCap":90156026},{"date":"2025-02-07","current":-4.026118,"twenty":-5.938508,"median":-4.309619,"eighty":-3.767526,"marketCap":85147358},{"date":"2025-02-14","current":-4.330615,"twenty":-5.916595,"median":-4.296782,"eighty":-3.799613,"marketCap":91587074},{"date":"2025-02-21","current":-3.72014,"twenty":-5.901986,"median":-4.296782,"eighty":-3.761786,"marketCap":85862882},{"date":"2025-02-28","current":-3.689139,"twenty":-5.807029,"median":-4.262949,"eighty":-3.720436,"marketCap":85147358},{"date":"2025-03-07","current":-3.162119,"twenty":-5.639027,"median":-4.229116,"eighty":-3.689139,"marketCap":72983450},{"date":"2025-03-14","current":-2.294087,"twenty":-5.507546,"median":-4.152992,"eighty":-3.653403,"marketCap":52948777},{"date":"2025-03-21","current":-1.891071,"twenty":-5.317631,"median":-4.127617,"eighty":-3.617985,"marketCap":43646965},{"date":"2025-03-28","current":-2.030577,"twenty":-5.251891,"median":-4.059951,"eighty":-3.565808,"marketCap":46866823},{"date":"2025-04-04","current":-2.191783,"twenty":-5.220193,"median":-4.053963,"eighty":-3.506186,"marketCap":50587548},{"date":"2025-04-11","current":-1.919282,"twenty":-5.198143,"median":-4.02178,"eighty":-3.38992,"marketCap":44298092},{"date":"2025-04-17","current":-2.002676,"twenty":-5.149629,"median":-4.014793,"eighty":-3.224122,"marketCap":46222851},{"date":"2025-04-25","current":-1.987175,"twenty":-5.113107,"median":-3.992285,"eighty":-3.104751,"marketCap":45865089},{"date":"2025-05-02","current":-2.759104,"twenty":-5.076585,"median":-3.944397,"eighty":-2.759104,"marketCap":63681637},{"date":"2025-05-09","current":-2.619599,"twenty":-4.930496,"median":-3.907874,"eighty":-2.693382,"marketCap":60461779},{"date":"2025-05-16","current":-2.437632,"twenty":-4.930496,"median":-3.890787,"eighty":-2.691522,"marketCap":63331031},{"date":"2025-05-23","current":-2.506208,"twenty":-4.784407,"median":-3.875146,"eighty":-2.619599,"marketCap":65112685},{"date":"2025-05-30","current":-2.451953,"twenty":-4.784407,"median":-3.871352,"eighty":-2.502848,"marketCap":63703103},{"date":"2025-06-06","current":-2.671453,"twenty":-4.755189,"median":-3.805483,"eighty":-2.487546,"marketCap":69405829}],"updateTime":1749375297524}}}